Radiopharmaceuticals Market

List of Tables

Radiopharmaceuticals Market- Scope of Report

TMR's report on the global Radiopharmaceuticals Marketstudies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the Market during the forecast period from 2025 to 2035. The report provides revenue of the global Radiopharmaceuticals Marketfor the period 2025 to 2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Radiopharmaceuticals Marketfrom 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Radiopharmaceuticals Market .

Market Snapshot
Market Value in 2024	US$ 6.6 Bn
Market Value in 2035	US$ 14.6 Bn
CAGR	7.6%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Radiopharmaceuticals Market .

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Radiopharmaceuticals Market . These serve as valuable tools for existing Market players as well as for entities interested in participating in the global Radiopharmaceuticals Market .

The report delves into the competitive landscape of the global Radiopharmaceuticals Market . Key players operating in the global Radiopharmaceuticals Markethave been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Radiopharmaceuticals Marketprofiled in this report.

Key Questions Answered in Global Radiopharmaceuticals MarketReport:

What are the opportunities in the global Radiopharmaceuticals Market ?
What are the major drivers, restraints, opportunities, and threats in the Market ?
Which regional Market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2035?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the Market positions of different companies operating in the global Market ?

Radiopharmaceuticals Market- Research Objectives and Research Approach

The comprehensive report on the global Radiopharmaceuticals Marketbegins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the Market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the Market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Radiopharmaceuticals Marketin terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the Market share for each of these at the end of 2035 has been provided. Such valuable insights enable Market stakeholders in making informed business decisions for investment in the global Radiopharmaceuticals Market .

Product Code: TMRGL213

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Radiopharmaceuticals Market

4. Market Overview

4.1. Introduction
- 4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Radiopharmaceuticals Market Analysis and Forecast, 2020 to 2035
- 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

5.1. FDA Approved Radiopharmaceuticals Products
5.2. Epidemiology of Major Diseases
5.3. Reimbursement Scenario by key Countries/Regions
5.4. Pricing Analysis
5.5. Pipeline Analysis
5.6. Technological Advancements & Development
5.7. Insights on Pioneering Targeted in Radiotherapy
5.8. Regulatory Scenario by Country/Regions
5.9. Key Industry Events (Product Launch, Key Mergers and Acquisitions, etc.)
5.10. Number of Radiotherapy Centers: Major Country

6. Global Radiopharmaceuticals Market Analysis and Forecast, by Radioisotopes

6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Radioisotopes, 2020 to 2035
- 6.3.1. Diagnostics
  - 6.3.1.1. Fluorine-18 (F-18)
    - 6.3.1.1.1. Fludeoxyglucose (FDG)
    - 6.3.1.1.2. Sodium Fluoride
    - 6.3.1.1.3. Flucicovine
    - 6.3.1.1.4. Florbetapir
    - 6.3.1.1.5. Florbetaben
    - 6.3.1.1.6. Others
  - 6.3.1.2. Gallium-68 (Ga-68)
    - 6.3.1.2.1. Dotatate
    - 6.3.1.2.2. Dotatoc
    - 6.3.1.2.3. PSMA-11
  - 6.3.1.3. Technetium-99m (Tc-99)
  - 6.3.1.4. Iodine-123 (I-123)
  - 6.3.1.5. Others
- 6.3.2. Therapy
  - 6.3.2.1. Iodine-131 (I-131)
  - 6.3.2.2. Yttrium-90 (Y-90)
  - 6.3.2.3. Lutetium-177 (Lu-177)
    - 6.3.2.3.1. Lu-PSMA-617
    - 6.3.2.3.2. Lu-DOTA-TATE
  - 6.3.2.4. Others
6.4. Market Attractiveness Analysis, by Radioisotopes

7. Global Radiopharmaceuticals Market Analysis and Forecast, by Application

7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2020 to 2035
- 7.3.1. Oncology
  - 7.3.1.1. Prostate Cancer
  - 7.3.1.2. Breast Cancer
  - 7.3.1.3. Neuroendocrine Tumors
  - 7.3.1.4. Thyroid Cancer
  - 7.3.1.5. Colorectal Cancer
  - 7.3.1.6. Liver Cancer
  - 7.3.1.7. Others
- 7.3.2. Neurology
  - 7.3.2.1. Alzheimer's Disease
  - 7.3.2.2. Parkinson's Disease
  - 7.3.2.3. Others
- 7.3.3. Cardiology
- 7.3.4. Others
7.4. Market Attractiveness Analysis, by Application

8. Global Radiopharmaceuticals Market Analysis and Forecast, by End-user

8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2020 to 2035
- 8.3.1. Hospitals
- 8.3.2. Diagnostics and Imaging Centers
- 8.3.3. Others
8.4. Market Attractiveness Analysis, by End-user

9. Global Radiopharmaceuticals Market Analysis and Forecast, by Region

9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020 to 2035
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region

10. North America Radiopharmaceuticals Market Analysis and Forecast

10.1. Introduction
- 10.1.1. Key Findings
10.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
- 10.2.1. Diagnostics
  - 10.2.1.1. Fluorine-18 (F-18)
    - 10.2.1.1.1. Fludeoxyglucose (FDG)
    - 10.2.1.1.2. Sodium Fluoride
    - 10.2.1.1.3. Flucicovine
    - 10.2.1.1.4. Florbetapir
    - 10.2.1.1.5. Florbetaben
    - 10.2.1.1.6. Others
  - 10.2.1.2. Gallium-68 (Ga-68)
    - 10.2.1.2.1. Dotatate
    - 10.2.1.2.2. Dotatoc
    - 10.2.1.2.3. PSMA-11
  - 10.2.1.3. Technetium-99m (Tc-99)
  - 10.2.1.4. Iodine-123 (I-123)
  - 10.2.1.5. Others
- 10.2.2. Therapy
  - 10.2.2.1. Iodine-131 (I-131)
  - 10.2.2.2. Yttrium-90 (Y-90)
  - 10.2.2.3. Lutetium-177 (Lu-177)
    - 10.2.2.3.1. Lu-PSMA-617
    - 10.2.2.3.2. Lu-DOTA-TATE
  - 10.2.2.4. Others
10.3. Market Value Forecast, by Application, 2020 to 2035
- 10.3.1. Oncology
  - 10.3.1.1. Prostate Cancer
  - 10.3.1.2. Breast Cancer
  - 10.3.1.3. Neuroendocrine Tumors
  - 10.3.1.4. Thyroid Cancer
  - 10.3.1.5. Colorectal Cancer
  - 10.3.1.6. Liver Cancer
  - 10.3.1.7. Others
- 10.3.2. Neurology
  - 10.3.2.1. Alzheimer's Disease
  - 10.3.2.2. Parkinson's Disease
  - 10.3.2.3. Others
- 10.3.3. Cardiology
- 10.3.4. Others
10.4. Market Value Forecast, by End-user, 2020 to 2035
- 10.4.1. Hospitals
- 10.4.2. Diagnostics and Imaging Centers
- 10.4.3. Others
10.5. Market Value Forecast, by Country, 2020 to 2035
- 10.5.1. U.S.
- 10.5.2. Canada
10.6. Market Attractiveness Analysis
- 10.6.1. By Radioisotopes
- 10.6.2. By Application
- 10.6.3. By End-user
- 10.6.4. By Country

11. Europe Radiopharmaceuticals Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
- 11.2.1. Diagnostics
  - 11.2.1.1. Fluorine-18 (F-18)
    - 11.2.1.1.1. Fludeoxyglucose (FDG)
    - 11.2.1.1.2. Sodium Fluoride
    - 11.2.1.1.3. Flucicovine
    - 11.2.1.1.4. Florbetapir
    - 11.2.1.1.5. Florbetaben
    - 11.2.1.1.6. Others
  - 11.2.1.2. Gallium-68 (Ga-68)
    - 11.2.1.2.1. Dotatate
    - 11.2.1.2.2. Dotatoc
    - 11.2.1.2.3. PSMA-11
  - 11.2.1.3. Technetium-99m (Tc-99)
  - 11.2.1.4. Iodine-123 (I-123)
  - 11.2.1.5. Others
- 11.2.2. Therapy
  - 11.2.2.1. Iodine-131 (I-131)
  - 11.2.2.2. Yttrium-90 (Y-90)
  - 11.2.2.3. Lutetium-177 (Lu-177)
    - 11.2.2.3.1. Lu-PSMA-617
    - 11.2.2.3.2. Lu-DOTA-TATE
  - 11.2.2.4. Others
11.3. Market Value Forecast, by Application, 2020 to 2035
- 11.3.1. Oncology
  - 11.3.1.1. Prostate Cancer
  - 11.3.1.2. Breast Cancer
  - 11.3.1.3. Neuroendocrine Tumors
  - 11.3.1.4. Thyroid Cancer
  - 11.3.1.5. Colorectal Cancer
  - 11.3.1.6. Liver Cancer
  - 11.3.1.7. Others
- 11.3.2. Neurology
  - 11.3.2.1. Alzheimer's Disease
  - 11.3.2.2. Parkinson's Disease
  - 11.3.2.3. Others
- 11.3.3. Cardiology
- 11.3.4. Others
11.4. Market Value Forecast, by End-user, 2020 to 2035
- 11.4.1. Hospitals
- 11.4.2. Diagnostics and Imaging Centers
- 11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
- 11.5.1. Germany
- 11.5.2. UK
- 11.5.3. France
- 11.5.4. Italy
- 11.5.5. Spain
- 11.5.6. Switzerland
- 11.5.7. The Netherlands
- 11.5.8. Rest of Europe
11.6. Market Attractiveness Analysis
- 11.6.1. By Radioisotopes
- 11.6.2. By Application
- 11.6.3. By End-user
- 11.6.4. By Country/Sub-region

12. Asia Pacific Radiopharmaceuticals Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
- 12.2.1. Diagnostics
  - 12.2.1.1. Fluorine-18 (F-18)
    - 12.2.1.1.1. Fludeoxyglucose (FDG)
    - 12.2.1.1.2. Sodium Fluoride
    - 12.2.1.1.3. Flucicovine
    - 12.2.1.1.4. Florbetapir
    - 12.2.1.1.5. Florbetaben
    - 12.2.1.1.6. Others
  - 12.2.1.2. Gallium-68 (Ga-68)
    - 12.2.1.2.1. Dotatate
    - 12.2.1.2.2. Dotatoc
    - 12.2.1.2.3. PSMA-11
  - 12.2.1.3. Technetium-99m (Tc-99)
  - 12.2.1.4. Iodine-123 (I-123)
  - 12.2.1.5. Others
- 12.2.2. Therapy
  - 12.2.2.1. Iodine-131 (I-131)
  - 12.2.2.2. Yttrium-90 (Y-90)
  - 12.2.2.3. Lutetium-177 (Lu-177)
    - 12.2.2.3.1. Lu-PSMA-617
    - 12.2.2.3.2. Lu-DOTA-TATE
  - 12.2.2.4. Others
12.3. Market Value Forecast, by Application, 2020 to 2035
- 12.3.1. Oncology
  - 12.3.1.1. Prostate Cancer
  - 12.3.1.2. Breast Cancer
  - 12.3.1.3. Neuroendocrine Tumors
  - 12.3.1.4. Thyroid Cancer
  - 12.3.1.5. Colorectal Cancer
  - 12.3.1.6. Liver Cancer
  - 12.3.1.7. Others
- 12.3.2. Neurology
  - 12.3.2.1. Alzheimer's Disease
  - 12.3.2.2. Parkinson's Disease
  - 12.3.2.3. Others
- 12.3.3. Cardiology
- 12.3.4. Others
12.4. Market Value Forecast, by End-user, 2020 to 2035
- 12.4.1. Hospitals
- 12.4.2. Diagnostics and Imaging Centers
- 12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
- 12.5.1. China
- 12.5.2. Japan
- 12.5.3. India
- 12.5.4. South Korea
- 12.5.5. Australia & Newzealend
- 12.5.6. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
- 12.6.1. By Radioisotopes
- 12.6.2. By Application
- 12.6.3. By End-user
- 12.6.4. By Country/Sub-region

13. Latin America Radiopharmaceuticals Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
- 13.2.1. Diagnostics
  - 13.2.1.1. Fluorine-18 (F-18)
    - 13.2.1.1.1. Fludeoxyglucose (FDG)
    - 13.2.1.1.2. Sodium Fluoride
    - 13.2.1.1.3. Flucicovine
    - 13.2.1.1.4. Florbetapir
    - 13.2.1.1.5. Florbetaben
    - 13.2.1.1.6. Others
  - 13.2.1.2. Gallium-68 (Ga-68)
    - 13.2.1.2.1. Dotatate
    - 13.2.1.2.2. Dotatoc
    - 13.2.1.2.3. PSMA-11
  - 13.2.1.3. Technetium-99m (Tc-99)
  - 13.2.1.4. Iodine-123 (I-123)
  - 13.2.1.5. Others
- 13.2.2. Therapy
  - 13.2.2.1. Iodine-131 (I-131)
  - 13.2.2.2. Yttrium-90 (Y-90)
  - 13.2.2.3. Lutetium-177 (Lu-177)
    - 13.2.2.3.1. Lu-PSMA-617
    - 13.2.2.3.2. Lu-DOTA-TATE
  - 13.2.2.4. Others
13.3. Market Value Forecast, by Application, 2020 to 2035
- 13.3.1. Oncology
  - 13.3.1.1. Prostate Cancer
  - 13.3.1.2. Breast Cancer
  - 13.3.1.3. Neuroendocrine Tumors
  - 13.3.1.4. Thyroid Cancer
  - 13.3.1.5. Colorectal Cancer
  - 13.3.1.6. Liver Cancer
  - 13.3.1.7. Others
- 13.3.2. Neurology
  - 13.3.2.1. Alzheimer's Disease
  - 13.3.2.2. Parkinson's Disease
  - 13.3.2.3. Others
- 13.3.3. Cardiology
- 13.3.4. Others
13.4. Market Value Forecast, by End-user, 2020 to 2035
- 13.4.1. Hospitals
- 13.4.2. Diagnostics and Imaging Centers
- 13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
- 13.5.1. Brazil
- 13.5.2. Mexico
- 13.5.3. Argentina
- 13.5.4. Rest of Latin America
13.6. Market Attractiveness Analysis
- 13.6.1. By Radioisotopes
- 13.6.2. By Application
- 13.6.3. By End-user
- 13.6.4. By Country/Sub-region

14. Middle East & Africa Radiopharmaceuticals Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
- 14.2.1. Diagnostics
  - 14.2.1.1. Fluorine-18 (F-18)
    - 14.2.1.1.1. Fludeoxyglucose (FDG)
    - 14.2.1.1.2. Sodium Fluoride
    - 14.2.1.1.3. Flucicovine
    - 14.2.1.1.4. Florbetapir
    - 14.2.1.1.5. Florbetaben
    - 14.2.1.1.6. Others
  - 14.2.1.2. Gallium-68 (Ga-68)
    - 14.2.1.2.1. Dotatate
    - 14.2.1.2.2. Dotatoc
    - 14.2.1.2.3. PSMA-11
  - 14.2.1.3. Technetium-99m (Tc-99)
  - 14.2.1.4. Iodine-123 (I-123)
  - 14.2.1.5. Others
- 14.2.2. Therapy
  - 14.2.2.1. Iodine-131 (I-131)
  - 14.2.2.2. Yttrium-90 (Y-90)
  - 14.2.2.3. Lutetium-177 (Lu-177)
    - 14.2.2.3.1. Lu-PSMA-617
    - 14.2.2.3.2. Lu-DOTA-TATE
  - 14.2.2.4. Others
14.3. Market Value Forecast, by Application, 2020 to 2035
- 14.3.1. Oncology
  - 14.3.1.1. Prostate Cancer
  - 14.3.1.2. Breast Cancer
  - 14.3.1.3. Neuroendocrine Tumors
  - 14.3.1.4. Thyroid Cancer
  - 14.3.1.5. Colorectal Cancer
  - 14.3.1.6. Liver Cancer
  - 14.3.1.7. Others
- 14.3.2. Neurology
  - 14.3.2.1. Alzheimer's Disease
  - 14.3.2.2. Parkinson's Disease
  - 14.3.2.3. Others
- 14.3.3. Cardiology
- 14.3.4. Others
14.4. Market Value Forecast, by End-user, 2020 to 2035
- 14.4.1. Hospitals
- 14.4.2. Diagnostics and Imaging Centers
- 14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
- 14.5.1. GCC Countries
- 14.5.2. South Africa
- 14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
- 14.6.1. By Radioisotopes
- 14.6.2. By Application
- 14.6.3. By End-user
- 14.6.4. By Country/Sub-region

15. Competition Landscape

15.1. Market Player - Competition Matrix (By Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2024)
15.3. Company Profiles
- 15.3.1. Advanced Accelerator Applications
  - 15.3.1.1. Company Overview
  - 15.3.1.2. Financial Overview
  - 15.3.1.3. Product Portfolio
  - 15.3.1.4. Business Strategies
  - 15.3.1.5. Recent Developments
- 15.3.2. Bayer AG
  - 15.3.2.1. Company Overview
  - 15.3.2.2. Financial Overview
  - 15.3.2.3. Product Portfolio
  - 15.3.2.4. Business Strategies
  - 15.3.2.5. Recent Developments
- 15.3.3. Eli Lilly and Company
  - 15.3.3.1. Company Overview
  - 15.3.3.2. Financial Overview
  - 15.3.3.3. Product Portfolio
  - 15.3.3.4. Business Strategies
  - 15.3.3.5. Recent Developments
- 15.3.4. GE Healthcare
  - 15.3.4.1. Company Overview
  - 15.3.4.2. Financial Overview
  - 15.3.4.3. Product Portfolio
  - 15.3.4.4. Business Strategies
  - 15.3.4.5. Recent Developments
- 15.3.5. ITM Isotopen Technologien Munchen AG
  - 15.3.5.1. Company Overview
  - 15.3.5.2. Financial Overview
  - 15.3.5.3. Product Portfolio
  - 15.3.5.4. Business Strategies
  - 15.3.5.5. Recent Developments
- 15.3.6. Jubilant Pharma Limited
  - 15.3.6.1. Company Overview
  - 15.3.6.2. Financial Overview
  - 15.3.6.3. Product Portfolio
  - 15.3.6.4. Business Strategies
  - 15.3.6.5. Recent Developments
- 15.3.7. Lantheus Holdings, Inc.
  - 15.3.7.1. Company Overview
  - 15.3.7.2. Financial Overview
  - 15.3.7.3. Product Portfolio
  - 15.3.7.4. Business Strategies
  - 15.3.7.5. Recent Developments
- 15.3.8. Nihon Medi-Physics
  - 15.3.8.1. Company Overview
  - 15.3.8.2. Financial Overview
  - 15.3.8.3. Product Portfolio
  - 15.3.8.4. Business Strategies
  - 15.3.8.5. Recent Developments
- 15.3.9. Siemens Healthineers AG
  - 15.3.9.1. Company Overview
  - 15.3.9.2. Financial Overview
  - 15.3.9.3. Product Portfolio
  - 15.3.9.4. Business Strategies
  - 15.3.9.5. Recent Developments
- 15.3.10. Telix Pharmaceuticals
  - 15.3.10.1. Company Overview
  - 15.3.10.2. Financial Overview
  - 15.3.10.3. Product Portfolio
  - 15.3.10.4. Business Strategies
  - 15.3.10.5. Recent Developments

Product Code: TMRGL213

List of Tables

Table 01: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
Table 02: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
Table 03: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
Table 04: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
Table 05: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
Table 06: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
Table 07: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 08: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
Table 09: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
Table 10: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 11: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Region, 2020 to 2035
Table 12: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, by Country, 2020 to 2035
Table 13: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
Table 14: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
Table 15: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
Table 16: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
Table 17: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
Table 18: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
Table 19: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 20: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
Table 21: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
Table 22: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 23: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
Table 24: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
Table 25: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
Table 26: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
Table 27: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
Table 28: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
Table 29: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
Table 30: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 31: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
Table 32: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
Table 33: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 34: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
Table 35: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
Table 36: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
Table 37: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
Table 38: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
Table 39: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
Table 40: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
Table 41: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 42: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
Table 43: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
Table 44: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 45: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
Table 46: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
Table 47: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
Table 48: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
Table 49: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
Table 50: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
Table 51: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
Table 52: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 53: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
Table 54: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
Table 55: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 56: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
Table 57: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
Table 58: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
Table 59: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
Table 60: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
Table 61: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
Table 62: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
Table 63: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 64: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
Table 65: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
Table 66: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035

List of Figures

Figure 01: Global Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
Figure 02: Global Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
Figure 03: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Diagnostics, 2020 to 2035
Figure 04: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Therapy, 2020 to 2035
Figure 05: Global Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
Figure 06: Global Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 07: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Oncology, 2020 to 2035
Figure 08: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Neurology, 2020 to 2035
Figure 09: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Cardiology, 2020 to 2035
Figure 10: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 11: Global Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
Figure 12: Global Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 13: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Hospitals, 2020 to 2035
Figure 14: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Diagnostics and Imaging Centers, 2020 to 2035
Figure 15: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 16: Global Radiopharmaceuticals Market Value Share Analysis, By Region, 2024 and 2035
Figure 17: Global Radiopharmaceuticals Market Attractiveness Analysis, By Region, 2025 to 2035
Figure 18: North America - Radiopharmaceuticals Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 19: North America - Radiopharmaceuticals Market Value Share Analysis, by Country, 2024 and 2035
Figure 20: North America - Radiopharmaceuticals Market Attractiveness Analysis, by Country, 2025 to 2035
Figure 21: North America - Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
Figure 22: North America - Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
Figure 23: North America - Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
Figure 24: North America - Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 25: North America - Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
Figure 26: North America - Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 27: Europe - Radiopharmaceuticals Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 28: Europe - Radiopharmaceuticals Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 29: Europe - Radiopharmaceuticals Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 30: Europe Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
Figure 31: Europe Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
Figure 32: Europe - Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
Figure 33: Europe - Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 34: Europe - Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
Figure 35: Europe - Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 36: Asia Pacific - Radiopharmaceuticals Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 37: Asia Pacific - Radiopharmaceuticals Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 38: Asia Pacific - Radiopharmaceuticals Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 39: Asia Pacific - Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
Figure 40: Asia Pacific - Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
Figure 41: Asia Pacific - Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
Figure 42: Asia Pacific - Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 43: Asia Pacific - Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
Figure 44: Asia Pacific - Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 45: Latin America - Radiopharmaceuticals Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 46: Latin America - Radiopharmaceuticals Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 47: Latin America - Radiopharmaceuticals Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 48: Latin America - Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
Figure 49: Latin America - Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
Figure 50: Latin America - Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
Figure 51: Latin America - Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 52: Latin America - Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
Figure 53: Latin America - Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 54: Middle East & Africa - Radiopharmaceuticals Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 55: Middle East & Africa - Radiopharmaceuticals Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 56: Middle East & Africa - Radiopharmaceuticals Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 57: Middle East & Africa - Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
Figure 58: Middle East & Africa - Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
Figure 59: Middle East & Africa - Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
Figure 60: Middle East & Africa - Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 61: Middle East & Africa - Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
Figure 62: Middle East & Africa - Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035

Radiopharmaceuticals Market

Description

Table of Contents

List of Tables

Key Questions Answered in Global Radiopharmaceuticals MarketReport:

Table of Contents

1. Preface

2. Assumptions and Research Methodology

3. Executive Summary: Global Radiopharmaceuticals Market

4. Market Overview

5. Key Insights

6. Global Radiopharmaceuticals Market Analysis and Forecast, by Radioisotopes

7. Global Radiopharmaceuticals Market Analysis and Forecast, by Application

8. Global Radiopharmaceuticals Market Analysis and Forecast, by End-user

9. Global Radiopharmaceuticals Market Analysis and Forecast, by Region

10. North America Radiopharmaceuticals Market Analysis and Forecast

11. Europe Radiopharmaceuticals Market Analysis and Forecast

12. Asia Pacific Radiopharmaceuticals Market Analysis and Forecast

13. Latin America Radiopharmaceuticals Market Analysis and Forecast

14. Middle East & Africa Radiopharmaceuticals Market Analysis and Forecast

15. Competition Landscape

List of Tables

List of Figures